426
Participants
Start Date
September 1, 2021
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2030
Camrelizumab
The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
radiotherapy
The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
RECRUITING
Shanghai Chest Hospital, Shanghai
RECRUITING
Anyang Tumour Hospital, Anyang
RECRUITING
Sun yat-sen University Cancer Center, Guangzhou
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
Zhongshan Hospital of Fudan University, Shanghai
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Zhigang Li
OTHER